Blood Cancer United Secures $562,500 Grant for Outreach
The five-year partnership increases patient access to clinical trials and survivorship resources in the Central Valley.
Updated on Oct. 23, 2026 in Philanthropy
Live Poll
Do you believe local health organizations in your area provide sufficient support for families facing cancer?
Blood Cancer United secured a five-year grant partnership totaling $562,500 to expand patient support and clinical trial outreach in the region. The funding aims to increase awareness of emerging therapies as the local medical community advances new cancer treatment trials.
Why it matters
This grant expands the capacity for patient advocacy and educational outreach, directly connecting individuals in the Central Valley to resources for more than 100 types of blood cancers. By increasing trial visibility, the partnership serves as a bridge between specialized research and patient access.
The five-year grant partnership provides $562,500 to support outreach for patients navigating over 100 types of blood cancers. This funding arrives as local healthcare institutions scale clinical research, including trials for CAR-T cell therapy that began in 2025.
The players
Blood Cancer United
A support organization that provides financial assistance, clinical trial navigation, and education for patients with over 100 types of blood cancers.
Community Cancer Institute
A regional healthcare facility focused on specialized oncology care and advanced clinical research trials.
California Institute of Regenerative Medicine
A state entity that funds and supports stem cell and regenerative medicine research programs.
Alene Mestjian
The Executive Director of Blood Cancer United who oversees organizational strategy and patient service initiatives.
The details
The grant supports a structured program of patient education, survivorship workshops, and community outreach. Blood Cancer United coordinates with healthcare providers and local businesses to deliver bilingual resources, focusing on clinical trial navigation and access to newly emerging cancer therapies. These operational initiatives are designed to improve patient awareness and connection to professional support services.
Timeline
2025: CAR-T cell therapy entered hospital trial phases.
November 5, 2026: Winners announced at Philanthropy Excellence Awards.
Market Landscape
This partnership reflects the ongoing investment in regional clinical research initiatives supported by the California Institute of Regenerative Medicine. The organization's recognition at the upcoming Philanthropy Excellence Awards underscores the growing intersection between private philanthropy and specialized medical outreach.
Operators in the healthcare and non-profit sectors should monitor how these clinical trial outreach programs influence local patient referral networks. Businesses interested in community engagement should note the criteria highlighted during the upcoming Philanthropy Excellence Awards ceremony.
The takeaway
Increased funding for clinical trial navigation signals a regional priority on patient access to advanced therapies. Business leaders can track the impact of these initiatives by monitoring the organization's published survivorship workshop schedules and outreach benchmarks.
Further reading
For broader trends in regional support initiatives, visit Philanthropy.
Source note: This article includes information reported by The Business Journal.
Live Poll
Do you believe local health organizations in your area provide sufficient support for families facing cancer?
